Mst 3 (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Mst 3, is a Opioid analgesic presented as an oral formulation for systemic use. It is employed to treat moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Mst 3 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morphine Sulfate is an opioid analgesic used to manage pain across several clinical contexts.

- Acute postoperative pain: provides rapid analgesia after surgical procedures. - Cancer‑related pain: controls moderate to severe pain associated with malignant disease. - Chronic severe pain: offers long‑term relief for conditions such as severe musculoskeletal or neuropathic pain when other treatments have failed.

Morphine Sulfate may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting - Constipation - Drowsiness or sedation - Dizziness - Sweating - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Anaphylactic or severe allergic reaction - Adrenal insufficiency - Seizures - Physical dependence, tolerance, or addiction

When prescribing or dispensing Morphine Sulfate, several safety considerations are essential.

- Pain assessment: verify that pain severity justifies opioid therapy. - Organ function: evaluate hepatic and renal function before initiation. - Respiratory monitoring: observe for signs of respiratory depression, especially after dose adjustments. - Elderly patients: start with lower doses and titrate cautiously. - Concomitant CNS depressants: avoid or closely monitor use with benzodiazepines, alcohol, or other sedatives. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Morphine Sulfate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines): additive respiratory depression. - Alcohol: potentiates sedative effects and respiratory compromise.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase morphine plasma levels. - Antihistamines: can enhance sedation. - Diuretics: may exacerbate hypotension.